Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorvardur R Halfdanarson

Showing results (171-180 of 213) with videos related to

Pageof 22
Sort By:
JCO Precision Oncology|March 25, 2026
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal CarcinomaFares Jamal, Oudai Sahwan, Seyi Abidoye, et al.
Annals of Surgical Oncology|October 3, 2025
Carcinoid Syndrome Impacts Long-Term Outcomes After Hepatectomy for Small Bowel Neuroendocrine Tumor Liver MetastasisMarkus Ammann, Hallbera Gudmundsdottir, Elizabeth B Habermann, et al.
Cancers|February 11, 2023
Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United StatesAmro M Abdelrahman, Jun Yin, Roberto Alva-Ruiz, et al.
Annals of Surgical Oncology|May 8, 2024
Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive HepatectomyMarkus Ammann, Hallbera Gudmundsdottir, Hubert Hackl, et al.
Journal of Neuroendocrinology|February 13, 2025
Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumorsHallbera Gudmundsdottir, Rondell P Graham, Patricia T Greipp, et al.
Investigational New Drugs|August 31, 2021
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinomaDaniel H Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 23, 2024
Surgical and oncologic outcomes for liver resections of cystic neuroendocrine tumor liver metastasisMarkus Ammann, Stella K Adjei Antwi, Hallbera Gudmundsdottir, et al.
JAMA Network Open|February 18, 2022
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical TrialNiharika B Mettu, Fang-Shu Ou, Tyler J Zemla, et al.
JAMA Oncology|April 26, 2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysisYucai Wang, Shouhao Zhou, Fang Yang, et al.
Lancet (London, England)|June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
Pageof 22

Showing results (171-180 of 213) with videos related to

Sort By:
Pageof 22
JCO Precision Oncology|March 25, 2026
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal CarcinomaFares Jamal, Oudai Sahwan, Seyi Abidoye, et al.
Annals of Surgical Oncology|October 3, 2025
Carcinoid Syndrome Impacts Long-Term Outcomes After Hepatectomy for Small Bowel Neuroendocrine Tumor Liver MetastasisMarkus Ammann, Hallbera Gudmundsdottir, Elizabeth B Habermann, et al.
Cancers|February 11, 2023
Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United StatesAmro M Abdelrahman, Jun Yin, Roberto Alva-Ruiz, et al.
Annals of Surgical Oncology|May 8, 2024
Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive HepatectomyMarkus Ammann, Hallbera Gudmundsdottir, Hubert Hackl, et al.
Journal of Neuroendocrinology|February 13, 2025
Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumorsHallbera Gudmundsdottir, Rondell P Graham, Patricia T Greipp, et al.
Investigational New Drugs|August 31, 2021
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinomaDaniel H Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 23, 2024
Surgical and oncologic outcomes for liver resections of cystic neuroendocrine tumor liver metastasisMarkus Ammann, Stella K Adjei Antwi, Hallbera Gudmundsdottir, et al.
JAMA Network Open|February 18, 2022
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical TrialNiharika B Mettu, Fang-Shu Ou, Tyler J Zemla, et al.
JAMA Oncology|April 26, 2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysisYucai Wang, Shouhao Zhou, Fang Yang, et al.
Lancet (London, England)|June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
Pageof 22